PALO ALTO, Calif., April 17 /PRNewswire-FirstCall/ -- Telik, Inc. announced that the presentation today of new preclinical studies of TELCYTA(R) (canfosfamide HCl, TLK286) that support clinical evaluation of the triplet combination of TELCYTA, carboplatin and paclitaxel in the treatment of advanced non-small cell lung and ovarian cancer. The company also reported studies demonstrating the anti-angiogenic activity of TELCYTA alone and in combination with bevacizumab. The data were presented at the 98th annual meeting of the American Association for Cancer Research (AACR) in Los Angeles.
One series of studies focused on cellular and molecular correlates of synergistic cancer cell growth inhibition caused by TELCYTA, carboplatin or paclitaxel alone and in doublet and triplet combinations in human lung cancer cells. The triplet combination of TELCYTA, carboplatin and paclitaxel resulted in significantly enhanced cancer cell cycle arrest compared to the single agents alone or the carboplatin/paclitaxel doublet combination. Compared to the single agents, the combination of TELCYTA and paclitaxel increased apoptosis and cell cycle arrest in the cancer cells. These studies support the positive clinical data from the Phase 2 study of TELCYTA plus carboplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer, reported earlier today at the AACR meeting.
A separate series of studies evaluated the anti-angiogenic effects of TELCYTA with and without bevacizumab, an approved anti-angiogenic agent. The studies demonstrated that TELCYTA is a potent inhibitor of human endothelial cell proliferation in vitro. When TELCYTA and bevacizumab were combined, the inhibitory effects on endothelial cell proliferation and capillary tubule formation were significantly enhanced. These studies suggest the potential for TELCYTA use in combination with bevacizumab and other anti-angiogenic agents.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.
This press release contains “forward-looking” statements, including statements regarding the potential for TELCYTA to treat one or more types of cancer. There are important factors that could cause Telik’s results to differ materially from those indicated by these forward-looking statements, including, among others, that none of Telik’s product candidates have been determined to be safe or effective in humans or been approved for marketing, clinical trials of Telik’s product candidates may take several years to complete and may not be successful, success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful and interim results of clinical trials do not necessarily predict final results. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2006. Telik does not undertake any obligation to update forward-looking statements contained in this press release.
TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, cdeguzman@telik.com
Web site: http://www.telik.com/
